From: The endless frontier? The recent increase of R&D productivity in pharmaceuticals
O\(\rightarrow\)D | Transition rates | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Preclinical | Phase I | Phase II | Phase III | Registration | ||||||
90 | 00 | 90 | 00 | 90 | 00 | 90 | 00 | 90 | 00 | |
ni\(\rightarrow\)ph | − 0.107 | − 0.009 | − 0.047 | 0.020 | − 0.079 | 0.024 | − 0.067 | 0.011 | − 0.109\(^{\dagger }\) | 0.016 |
bt\(\rightarrow\)ph | − 0.044 | − 0.029 | − 0.005 | − 0.048 | − 0.009 | − 0.042 | − 0.080 | 0.001 | − 0.067 | 0.027 |
ni\(\rightarrow\)ni | − 0.291\(^{\dagger }\) | − 0.275\(^{\dagger }\) | − 0.232\(^{\dagger }\) | − 0.212\(^{\dagger }\) | − 0.188\(^{\dagger }\) | − 0.155\(^{\dagger }\) | − 0.148\(^{\dagger }\) | − 0.094\(^{\dagger }\) | − 0.145\(^{\dagger }\) | − 0.047\(^{\dagger }\) |
ni\(\rightarrow\)bt | − 0.281\(^{\dagger }\) | − 0.050 | − 0.208\(^{\dagger }\) | − 0.070 | − 0.199\(^{\dagger }\) | − 0.136\(^{\dagger }\) | − 0.150\(^{\dagger }\) | − 0.111\(^{\dagger }\) | − 0.153\(^{\dagger }\) | − 0.035 |
bt\(\rightarrow\)bt | − 0.261\(^{\dagger }\) | − 0.083\(^{\dagger }\) | − 0.047 | − 0.081\(^{\dagger }\) | − 0.327\(^{\dagger }\) | − 0.111\(^{\dagger }\) | − 0.197\(^{\dagger }\) | − 0.159 | 0.024 | 0.120 |
O\(\rightarrow\)D | Sales (log\(_{10}\)€) | Orphan (%) | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
90 | 00 | 90 | 00 | |||||||
ni\(\rightarrow\)ph | 0.773\(^{\dagger }\) | 0.123 | 9.3 | 9.3 | ||||||
bt\(\rightarrow\)ph | 0.168 | − 0.350\(^{\dagger }\) | 10.3 | 14.2 | ||||||
ni\(\rightarrow\)ni | 0.116 | − 1.064\(^{\dagger }\) | 11.3 | 10.1 | ||||||
ni\(\rightarrow\)bt | 0.123 | − 0.598\(^{\dagger }\) | 8.1 | 13.4 | ||||||
bt\(\rightarrow\)bt | 0.228 | − 0.325\(^{\dagger }\) | 6.7 | 14.6 |